Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors

医学 曲妥珠单抗 癌症研究 酪氨酸激酶 突变 点突变 肺癌 癌症 肿瘤科 内科学 乳腺癌 生物 受体 基因 遗传学
作者
Monique B. Nilsson,Alissa Poteete,Hibiki Udagawa,Xiaoxing Yu,Junqin He,Xiuning Le,John V. Heymach
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 383-383 被引量:8
标识
DOI:10.1158/1538-7445.am2023-383
摘要

Abstract Activating ERBB2 (HER2) mutations occur across multiple malignancies, and although mutational hotpots vary by disease, HER2 mutations most frequently occur in the tyrosine kinase domain. Among lung cancer patients, the most common HER2 mutation is the exon 20 insertion mutations, Y772dupYVMA, which accounts for over 30% of all HER2 mutations in lung cancer. Recent clinical testing of trastuzumab deruxtecan (T-DXd), a HER2 antibody-drug conjugate (ADC), against HER2 mutant non-small cell lung cancer (NSCLC) demonstrated a confirmed objective response of 55%, a median duration of response of 9.3 months, and a median overall survival of 17.8 months, which ultimately led to the recent approval of T-DXd for HER2 mutant NSCLC. Acquired resistance to targeted agents remains a major clinical challenge, and HER2-mutant patients that initially respond to T-DXd will eventually develop progressive disease. Thus, understanding mechanism of T-DXd resistance and identifying targeted agents that remain effective in cells with acquired T-DXd resistance is of great clinical importance. We generated Ba/F3 cells expressing the HER2 YVMA mutation and assessed sensitivity to HER2 targeting agents by Cell Titer Glo assay. HER2 YVMA cells were sensitive to the EGFR/HER2 tyrosine kinase inhibitor (TKI) poziotinib and the HER2 ADC T-DXd. To generate HER2 ADC resistant cells, we cultured Ba/F3 HER2 YVMA cells in T-DXd continuously for 8 weeks at which point cells resumed rapid proliferation. Cell Titer Glo assay confirmed that Ba/F3 HER2 YVMA cells were sensitive to T-DXd with an IC50 of 195 μg/ml, whereas Ba/F3 HER2 YVMA T-DXd-resistant cells had an IC50 of greater than 1000 μg/ml. Notably, T-DXd resistant cells remained highly sensitive to the HER2 TKI poziotinib with an IC50 of 14 nM and 7.5 nM for T-DXd-resistant and parental cells, respectively. Moreover, T-DXd-resistant cells demonstrated reduced sensitivity to the topoisomerase inhibitor topotecan with an IC50 of 200 nM whereas parental cells had an IC50 of 66 nM, suggesting that acquired T-DXd resistance may be mediated by loss of sensitivity to the ADC payload. Collectively, these data demonstrate that HER2 TKIs such as poziotinib may retain anti-tumor cell activity in HER2 mutant tumor cells with acquired resistance to HER2 ADCs. Citation Format: Monique B. Nilsson, Alissa Poteete, Hibiki Udagawa, Xiaoxing Yu, Junqin He, Xiuning Le, John Heymach. Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 383.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小马甲的应助被zdenglong采纳,获得10
1秒前
Monster完成签到,获得积分20
1秒前
1秒前
山北大花萼完成签到,获得积分10
2秒前
乐乐的应助被小饭采纳,获得10
2秒前
zch完成签到,获得积分10
3秒前
3秒前
秋风的应助被吱吱采纳,获得10
3秒前
4秒前
七七发布了新的文献求助10
4秒前
小董完成签到,获得积分20
4秒前
单薄冰安发布了新的文献求助10
4秒前
精明的如音完成签到,获得积分10
5秒前
酷波er的应助被楠楠采纳,获得10
5秒前
wanci的应助被echo采纳,获得10
5秒前
FOX发布了新的文献求助10
6秒前
6秒前
爆米花的应助被何文鑫采纳,获得10
6秒前
大模型的应助被wangfei采纳,获得10
6秒前
carpediem完成签到,获得积分10
6秒前
ZZt完成签到,获得积分10
6秒前
7秒前
chai发布了新的文献求助10
8秒前
worakls完成签到,获得积分10
8秒前
wg发布了新的文献求助10
8秒前
8秒前
门牙关注了科研通微信公众号
8秒前
慕青的应助被carpediem采纳,获得10
9秒前
10秒前
SCL987654321发布了新的文献求助10
10秒前
万能图书馆的应助被艾格采纳,获得10
10秒前
大模型的应助被sci采纳,获得30
12秒前
朴素香氛发布了新的文献求助10
12秒前
正直的惜文完成签到,获得积分20
12秒前
13秒前
sunziyi完成签到,获得积分20
13秒前
Hello的应助被青柳安采纳,获得10
13秒前
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188177
求助须知:如何正确求助?哪些是违规求助? 9575987
关于积分的说明 21844723
捐赠科研通 7785975
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482095